Skip to main content

Protalix PRX-102: Likely Approval Could Be A Game Changer

Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.